NATCO Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 8,979 million compared to INR 5,968 million a year ago. Revenue was INR 9.27 million compared to INR 6,106 million a year ago. Net income was INR 2,758 million compared to net loss of INR 505 million a year ago. Basic earnings per share from continuing operations was INR 15.11 compared to basic loss per share from continuing operations of INR 2.77 a year ago. Diluted earnings per share from continuing operations was INR 15.11 compared to diluted loss per share from continuing operations of INR 2.77 a year ago.
For the full year, sales was INR 27,071 million compared to INR 19,448 million a year ago. Revenue was INR 28,117 million compared to INR 20,438 million a year ago. Net income was INR 7,153 million compared to INR 1,700 million a year ago. Basic earnings per share from continuing operations was INR 39.18 compared to INR 9.32 a year ago. Diluted earnings per share from continuing operations was INR 39.18 compared to INR 9.32 a year ago.